Depemokimab
Medication
From Wikipedia, the free encyclopedia
Depemokimab, sold under the brand name Exdensur, is a humanized monoclonal antibody used for the treatment of asthma.[2][3] Depemokimab is an interleukin-5 (IL-5) antagonist monoclonal antibody (humanized immunoglobulin G1 [IgG1] kappa).[2] Depemokimab was developed by GSK.[4] It is structurally similar to mepolizumab but contains seven amino acid substitutions in the heavy chain sequence. [5]
| |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Interleukin 5 |
| Clinical data | |
| Trade names | Exdensur |
| Other names | AQ-82742999; GSK 294; GSK3511294, depemokimab-ulaa |
| AHFS/Drugs.com | exdensur |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
Depemokimab was approved for medical use in both the United Kingdom and United States in December 2025.[1][6]
Medical uses
In the United Kingdom, depemokimab is indicated as an add-on maintenance treatment of asthma in people aged twelve years of age and older with type 2 inflammation characterized by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids plus another asthma controller; and as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.[1]
In the United States, depemokimab is indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in people aged twelve years of age and older.[2]
Society and culture
Legal status
Depemokimab was approved for medical use in both the United Kingdom and United States in December 2025.[1][4][7]
In December 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Exdensur, intended for severe eosinophilic asthma and for severe chronic rhinosinusitis with nasal polyps.[8] The applicant for this medicinal product is GlaxoSmithKline Trading Services Limited.[8]
Names
Depemokimab is the international nonproprietary name.[9]
